References
- Langlois JA, Rutland-Brown W, Wald MM. The epidemiology and impact of traumatic brain injury: a brief overview. J Head Trauma Rehabil. 2006;21(5):375–378.
- Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), The Department Of Defence (DoD), The Department of Veterans’ Affairs (VA) Leadership Panel. Report to Congress on Traumatic Brain Injury in the United States : Understanding the Public Health Problem among Current and Former Military Personnel. Washington (DC): Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), The Department Of Defence (DoD), The Department of Veterans’ Affairs (VA) Leadership Panel; 2013.
- Fann JR, Katon WJ, Uomoto JM, et al. Psychiatric disorders and functional disability in outpatients with traumatic brain injuries. Am J Psychiatry [Internet]. 1995;152(10):1493–1499. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7573589
- Sundman MH, Hall EE, Chen N-K. Examining the relationship between head trauma and neurodegenerative disease: a review of epidemiology, pathology and neuroimaging techniques. J Alzheimer’s Dis Park [Internet]. 2014;04(01):1–21. Available from: http://www.omicsonline.org/open-access/examining-the-relationship-between-head-trauma-and-neurodegenerative-disease-2161-0460.1000137.php?aid=23260
- McConeghy KW, Hatton J, Hughes L, et al. A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury. CNS Drugs [Internet]. 2012;26(7):613–636. Available from:http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L365045261\nhttp://dx.doi.org/10.2165/11634020-000000000-00000\nhttp://sfxhosted.exlibrisgroup.com/dal?sid=EMBASE&issn=11727047&id=doi:10.2165/11634020-000000000-00000&atitle=A+rev.
- Marklund N, Bakshi A, Castelbuono DJ, et al. Evaluation of pharmacological treatment strategies in traumatic brain injury. Curr Pharm Des. 2006;12(13):1645–1680.
- Nichol A, French C, Little L, et al. Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial. Lancet [Internet]. 2015;6736(15):1–8. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0140673615003864
- Margulies S, Hicks R. Combination therapies for traumatic brain injury: prospective considerations. J Neurotrauma [Internet]. 2009;26(6):925–939. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19331514
- Rapoport M, Lorberboum-Galski H. TAT-based drug delivery system–new directions in protein delivery for new hopes?. Expert Opin Drug Deliv. 2009;6(5):453–463.
- Meloni BP, Craig AJ, Milech N, et al. The neuroprotective efficacy of cell-penetrating peptides TAT, penetratin, Arg-9, and Pep-1 in glutamic acid, kainic acid, and in vitro ischemia injury models using primary cortical neuronal cultures. Cell Mol Neurobiol. 2014;34(2):173–181.
- Meloni BP, Brookes LM, Clark VW, et al. Poly-arginine and arginine-rich peptides are neuroprotective in stroke models. J Cereb Blood Flow Metab [Internet]. 2015;35(6):993–1004. Available from: http://www.nature.com/doifinder/10.1038/jcbfm.2015.11
- Meloni BP, Milani D, Edwards AB, et al. Neuroprotective peptides fused to arginine-rich cell penetrating peptides: neuroprotective mechanism likely mediated by peptide endocytic properties. Pharmacol Ther [Internet]. 2015;153:36–54. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0163725815001175
- Vaslin A, Naegele-Tollardo S, Puyal J, et al. Excitotoxicity-induced endocytosis mediates neuroprotection by TAT-peptide-linked JNK inhibitor. J Neurochem. 2011;119(6):1243–1252.
- Ramos-Molina B, Lick AN, Nasrolahi Shirazi A, et al. Cationic cell-penetrating peptides are potent furin inhibitors. PLoS One [Internet]. 2015;10(6):e0130417. Available from: http://dx.plos.org/10.1371/journal.pone.0130417
- Del Gaizo V, MacKenzie JA, Payne RM. Targeting proteins to mitochondria using TAT. Mol Genet Metab [Internet]. 2003;80(1–2):170–180. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14567966
- Rigobello MP, Barzon E, Marin O, et al. Effect of polycation peptides on mitochondrial permeability transition. Biochem Biophys Res Commun [Internet]. 1995;217(1):144–149. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0006291X85727568
- Cheng G, Kong R, Zhang L, et al. Mitochondria in traumatic brain injury and mitochondrial-targeted multipotential therapeutic strategies. Br J Pharmacol [Internet]. 2012;167(4):699–719. Available from: http://doi.wiley.com/10.1111/j.1476-5381.2012.02025.x
- Jiang Y, Brody DL. Administration of COG1410 reduces axonal amyloid precursor protein immunoreactivity and microglial activation after controlled cortical impact in mice. J Neurotrauma. 2012;29(13):2332–2341.
- Laskowitz DT, McKenna SE, Song P, et al. COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury. J Neurotrauma. 2007;24(7):1093–1107.
- Kaufman NA, Beare JE, Tan AA, et al. COG1410, an apolipoprotein E-based peptide, improves cognitive performance and reduces cortical loss following moderate fluid percussion injury in the rat. Behav Brain Res [Internet]. 2010;214(2):395–401. Available from: http://dx.doi.org/10.1016/j.bbr.2010.06.017
- Corrigan F, Thornton E, Roisman LC, et al. The neuroprotective activity of the amyloid precursor protein against traumatic brain injury is mediated via the heparin binding site in residues 96-110. J Neurochem. 2014;128(1):196–204.
- McAdoo JD, Warner DS, Goldberg RN, et al. Intrathecal administration of a novel apoE-derived therapeutic peptide improves outcome following perinatal hypoxic-ischemic injury. Neurosci Lett. 2005;381(3):305–308.
- Bramlett HM, Dietrich WD. Pathophysiology of cerebral ischemia and brain trauma: similarities and differences. J Cereb Blood Flow Metab. 2004;24(2):133–150.
- Hill MD, Martin RH, Mikulis D, et al. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol [Internet]. 2012;11(11):942–950. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1474442212702259